<DOC>
	<DOCNO>NCT03061981</DOCNO>
	<brief_summary>This randomize , double blind , placebo control , single ascend dose study assess safety , tolerability , PK , PD IE metformin follow single oral dose DA-1241 healthy male subject .</brief_summary>
	<brief_title>A Study To Evaluate The Safety , Tolerability , PK PD Of DA-1241 In Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Subject voluntarily agree participate study sign Institutional Review Board ( IRB ) approve informed consent screening procedure perform . 2 . Male subject age 18 55 year ( inclusive ) screening . 3 . Body mass index ( BMI ) 18.5 32.0 kg/m2 ( inclusive ) screening . 4 . Medical history , vital sign , physical examination , standard 12lead ECGs laboratory investigation ( clinical chemistry , hematology urinalysis ) must clinically acceptable within laboratory reference range relevant laboratory test , unless PI considers deviation irrelevant purpose study . These assessment may repeat discretion PI . 5 . Subjects partner childbearing potential must willing use medically acceptable double barrier form contraception IMP administration least 3 month last day IMP administration . Subjects must donate sperm duration study least 3 month last day IMP administration . 6 . Is nonsmoker nontobacco/nicotine user confirm urine cotinine test screen admission EPCU . Nicotine product include , limited , tobacco cigarette , electronic cigarette , snuff , cigar , pipe , include hookah water pipe . The use nicotine patch gum ( e.g. , product use part smoke cessation program ) allow . 1 . Has know hypersensitivity component formulation DA 1241 excipients medicinal product similar chemical structure . 2 . Has history presence clinically significant neurologic , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal endocrine disease abnormality may impact ability subject participate potentially confound study result . 3 . Has glycated hemoglobin A1C ( HgbA1C ) â‰¥ 6.5 % consistent possible diabetes screen . 4 . Any disorder would interfere absorption , distribution , metabolism excretion drug . 5 . Any concurrent disease condition , opinion PI , would make subject unsuitable participation clinical study . 6 . Subject history drinking &gt; 21 unit alcohol per week ( 1 unit = 10 g pure alcohol = 250 mL beer [ 5 % ] 35 mL spirit [ 35 % ] 100 mL wine [ 12 % ] ) within 3 month prior admission EPCU . 7 . Have positive test result Hepatitis B surface antigen ( HBsAg ) , Hepatitis C virus antibody ( anti HCV ) human immunodeficiency virus 1 and/or 2 antibody ( anti HIV1 and/or 2 ) screening . 8 . History drug abuse positive urine drug test ( cocaine , amphetamine , barbiturate , opiate , benzodiazepine , cannabinoids , etc . ) screen Day 1 . 9 . Has donate lose 450 mL blood volume ( include plasmaphoresis ) , transfusion blood product within 3 month screen . 10 . Taking medication include prescription , herbal remedy , vitamin supplement , dietary supplement overthecounter ( OTC ) product within 14 day 5 halflives product ( whichever period longer ) admission EPCU . 11 . Has abnormal ( clinically significant ) ECG screen Day 1 . Entry subject abnormal ( clinically significant ) ECG must approve documented signature , PI medically qualify Subinvestigator . 12 . Has supine blood pressure ( BP ) outside range 90 140 mmHg , inclusive , systolic BP 50 90 mmHg , inclusive , diastolic BP , rest heart rate outside range 45 100 beat per minute ( bpm ) . If value range , assessment may repeat eligibility determination , screen admission Day 1 . 13 . Has correct QT interval use Fridericia 's correct formula ( QTcF ) interval great 450 msec PR interval outside range 120 220 msec . If value range , ECG may repeat eligibility determination , screen admission Day 1 . 14 . Has abnormal laboratory value suggest clinically significant underlying disease alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) value great 1.5 time upper limit normal ( ULN ) . Laboratory assessment may repeat confirm eligibility screen Day 1 . 15 . Participation another study experimental drug within 30 day 5 halflives , whichever longer , study 's screening visit . Participation define date last dose receive previous study . 16 . Unwilling abstain vigorous exercise within 48 hour Day 1 . 17 . Intake food drink contain grapefruit , Chinese grapefruit ( pomelo ) , star fruit , pomegranate Seville orange ( include marmalade ) within 48 hour admission EPCU . 18 . Have use alcohol within 72 hour prior screen within 72 hour prior admission EPCU . 19 . Is unlikely comply protocol requirement , instruction studyrelated restriction ; e.g. , uncooperative attitude , inability return followup visit improbability complete clinical study . 20 . Is studysite employee immediate family member dependent ( e.g. , spouse , parent , child sibling ) studysite employee involve conduct study . 21 . Has difficulty swallow 2 tablet time .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>